LLY
Another green light for Lilly
Eli Lilly just turned in another reassuring data point for Foundayo, also known as orforglipron. In the Phase 3 ACHIEVE-4 study, the drug met FDA cardiovascular risk requirements for diabetes development, which is the pharma version of clearing the bouncer before you get into the club.
Why investors should care
The topline results showed a 16% reduction in major adverse cardiovascular events versus insulin glargine, plus no hepatic safety signal in the liver-injury analysis. That matters because when you’re trying to turn a pill into a blockbuster, safety is basically the seatbelt, airbag, and crash test all in one.
The commercial angle
Lilly also said it plans to submit Foundayo to the FDA for type 2 diabetes by the end of Q2 under the Comparative New Product Verification pathway. Translation: the company is trying to move from “promising data” to “please let us sell this thing” as quickly as the rulebook allows.
The analyst cherry on top
Guggenheim reiterated its Buy rating and kept a $1,163 price target on the stock after the readout. That’s not a love letter, but it’s close enough — and for a company already being watched like a prize fight between obesity-drug contenders, every positive safety update helps.
Big picture: Lilly doesn’t just want to win on efficacy. It wants a clean safety story, too — and this trial gives the bulls one more brick in that wall.